All In Biotech

Drug Trial Radar · NCT06253871

A Phase 1/2 Study of IAM1363 in HER2 Cancers

A Phase 1/2 Study of IAM1363 in Participants With Advanced Cancers Harboring HER2 Alterations

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

463

Planned (sponsor's estimate)

Start

Mar 25, 2024

Primary completion

Oct 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Iambic Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Feb 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

Conditions

  • HER2 Mutation-Related Tumors
  • HER2
  • HER2-positive Breast Cancer
  • HER2 + Breast Cancer
  • Brain Metastases From Solid Tumors
  • Brain Metastases From HER2 and Breast Cancer
  • CNS Metastases
  • HER2-Positive Solid Tumors
  • NSCLC (Non-small Cell Lung Cancer)
  • HER2-positive Bladder Cancer
  • HER2-positive Colorectal Cancer
  • HER2 + Gastric Cancer
  • HER2-positive Gastroesophageal Cancer

Interventions

  • IAM1363Drug

    IAM1363 monotherapy

  • Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + trastuzumabDrug

    Cohort 4A

  • Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + zanidatamabDrug

    Cohort 4B

  • Oral treatment with IAM1363 capsules or tablets, administered in combination with T-DxdDrug

    Cohort 4C

  • Oral treatment with IAM1363 capsules or tablets, administered in combination with pembrolizumab +/- carboplatin +/- pemetrexedDrug

    Cohort 4D

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of dose limiting toxicities (DLTs) (Part 1 only)Time frame: 21 days
  2. Incidence and severity of adverse events (AEs)Time frame: Through 30 days after the last dose of study drug (up to 90 days for Cohort 4D)
  3. Pharmacokinetic (PK) parametersTime frame: Up to 42 days
  4. Confirmed objective response rate (cORR)Time frame: Through study completion, estimated as 57 months
  5. Confirmed central nervous system ORR (CNS-cORR)Time frame: Through study completion, estimated as 57 months
  6. Frequency of IAM1363 dose modifications, including treatment discontinuationsTime frame: Through 30 days after the last dose of study drug
  7. Incidence and severity of clinical laboratory abnormalitiesTime frame: Through 30 days post last dose of study drug
  8. Incidence of ECG abnormalitiesTime frame: Through 30 days after the last dose of study drug

Locations

53 sites in 8 countries. Site status is shown where the registry gives one.

  • UCSD Moores Cancer Center

    La Jolla, California · Recruiting

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • University of Colorado Cancer Center

    Aurora, Colorado · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • Comprehensive Hematology Oncology

    St. Petersburg, Florida · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Cancer Institute

    Detroit, Michigan · Recruiting

  • START - Midwest Cancer Research Center

    Grand Rapids, Michigan · Recruiting

  • Saint Luke's Cancer Institute

    Kansas City, Missouri · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Dartmouth Hitchcock Medical

    Lebanon, New Hampshire · Recruiting

  • Rutgers Cancer Institute

    New Brunswick, New Jersey · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Duke Cancer Institute

    Durham, North Carolina · Recruiting

  • University Hospital Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • OU Health Stephenson Cancer Center

    Oklahoma City, Oklahoma · Recruiting

  • Providence Cancer Institute

    Portland, Oregon · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Vanderbilt Ingram Cancer Center

    Nashville, Tennessee · Recruiting

  • NEXT Oncology - Austin

    Austin, Texas · Recruiting

  • Mary Crowley Cancer Research

    Dallas, Texas · Recruiting

  • MD Anderson Cancer Center - University of Texas

    Houston, Texas · Recruiting

  • START Mountain Region

    West Valley City, Utah · Recruiting

  • NEXT Oncology - Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • Centre Georges François Leclerc

    Dijon, France · Recruiting

  • Institut de Cancerologie de l'Ouest

    Saint-Herblain, France · Recruiting

  • Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole Institut Claudius Regaud "

    Toulouse, France · Recruiting

  • Cork University Hospital, Wilton

    Cork, Ireland · Recruiting

  • St. Vincent's University Hospital

    Dublin, Ireland · Recruiting

  • The START center Dublin

    Dublin, Dublin, Ireland · Recruiting

  • Azienda Ospedaliero Universitaria Careggi - Largo Giovanni Alessandro Brambilla 3

    Florence, Italy · Recruiting

  • Istituto Europeo di Oncologia (IEO)

    Milan, Italy · Recruiting

  • Grande Ospedale Metropolitano Niguarda

    Milan, Italy · Recruiting

  • Azienda Ospedaliera Universitaria Luigi Vanvitelli

    Naples, Italy · Recruiting

  • Netherlands Cancer Institute-Antoni van Leeuwenhoek

    Amsterdam, Netherlands · Recruiting

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.